Severe Chronic Neutropenia Clinical Trial
Official title:
Twelve-month Study on the Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia
Purpose of the study is to investigate the safety, immunogenicity and the efficacy of
Zarzio®/Filgrastim HEXAL® under chromic administration.
Study was initiated as a post marketing authorization commitment to European Medicines
Agency (EMA). Subsequent submission of long term safety and immunogenicity data from pooled
studies and post-marketing experience have addressed the commitment and study no longer
necessary to be continued and hence prematurely terminated.
No patients were ongoing in the study at the time of study termination.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT01852370 -
Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
|
Phase 1/Phase 2 | |
| Terminated |
NCT00909584 -
Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia
|
Phase 2 |